Grand River Aseptic Manufacturing (“GRAM”), a leading parenteral contract development and manufacturing organization (“CDMO”), congratulates Johnson & Johnson on receiving emergency use authorization from the Food and Drug Administration (“FDA”) for its single-shot COVID-19 vaccine
| GRAND RAPIDS, Mich., March 1, 2021 /PRNewswire/ -- Grand River Aseptic Manufacturing (“GRAM”), a leading parenteral contract development and manufacturing organization (“CDMO”), congratulates Johnson & Johnson on receiving emergency use authorization from the Food and Drug Administration (“FDA”) for its single-shot COVID-19 vaccine. GRAM is proud to partner with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to support the critical manufacture of their vaccine.
GRAM is proud to play a critical role in supporting Johnson & Johnson in the battle against COVID-19 “GRAM is proud to play a critical role in supporting Johnson & Johnson in the battle against COVID-19,” said GRAM President and CEO Tom Ross. “Our team is enthusiastic, dedicated and focused on supporting the fight against COVID-19 and we are honored to play a role in this very important mission.” GRAM is well-equipped with sophisticated facilities and state of the art equipment to support the manufacturing of this COVID-19 vaccine. By performing advanced aseptic fill and finishing services, GRAM is helping to ensure its supply of COVID-19 vaccine is available for the market. To do so, GRAM is utilizing its world-class large-scale fill/finish facility located in Grand Rapids, MI. About Grand River Aseptic Manufacturing, Inc. Follow GRAM on Facebook, LinkedIn and Twitter. Contact:
SOURCE Grand River Aseptic Manufacturing |
View original content to download multimedia:
